ACS Chemical Neuroscience
Research Article
(8) Bonner, T. I., Young, A. C., Brann, M. R., and Buckley, N. J. (1988)
Cloning and expression of the human and rat m5 muscarinic
acetylcholine receptor genes. Neuron 1, 403−410.
(9) Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M.,
Tantawy, M. N., Kane, A. S., Bridges, T. M., Kennedy, J. P., Bradley, S. R.,
Peterson, T. E., Ansari, M. S., Baldwin, R. M., Kessler, R. M., Deutch, A.
Y., Lah, J. J., Levey, A. I., Lindsley, C. W., and Conn, P. J. (2008) Novel
selective allosteric activator of the M1 muscarinic acetylcholine receptor
regulates amyloid processing and produces antipsychotic-like activity in
rats. J. Neurosci. 28, 10422−10433.
(21) Leach, K., Sexton, P. M., and Christopoulos, A. (2007) Allosteric
GPCR modulators: Taking advantage of permissive receptor
pharmacology. Trends Pharmacol. Sci. 28, 382−389.
(22) Leysen, J. E., Janssen, P. M., Schotte, A., Luyten, W. H., and
Megens, A. A. (1993) Interaction of antipsychotic drugs with
neurotransmitter receptor sites in vitro and in vivo in relation to
pharmacological and clinical effects: Role of 5HT2 receptors.
Psychopharmacology 112, S40−54.
(23) Schotte, A., Janssen, P. F., Megens, A. A., and Leysen, J. E. (1993)
Occupancy of central neurotransmitter receptors by risperidone,
clozapine and haloperidol, measured ex vivo by quantitative auto-
radiography. Brain Res. 631, 191−202.
(24) Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., Bright, J. L.,
Harrington, N. R., Hesselink, M. B., Kennett, G. A., Lightowler, S.,
Sheardown, M. J., Syed, R., Upton, R. L., Wadsworth, G., Weiss, S. M.,
and Wyatt, A. (2001) The muscarinic receptor agonist xanomeline has
an antipsychotic-like profile in the rat. J. Pharmacol. Exp. Ther. 299, 782−
792.
(25) Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., and Konopaske,
G. (2012) Glutamatergic synaptic dysregulation in schizophrenia:
therapeutic implications. Handb. Exp. Pharmacol., 267−295.
(26) Mathe, J. M., Nomikos, G. G., Blakeman, K. H., and Svensson, T.
H. (1999) Differential actions of dizocilpine (MK-801) on the
mesolimbic and mesocortical dopamine systems: Role of neuronal
activity. Neuropharmacology 38, 121−128.
(27) Moghaddam, B., Adams, B., Verma, A., and Daly, D. (1997)
Activation of glutamatergic neurotransmission by ketamine: A novel
step in the pathway from NMDA receptor blockade to dopaminergic
and cognitive disruptions associated with the prefrontal cortex. J.
Neurosci. 17, 2921−2927.
(28) Adams, B., and Moghaddam, B. (1998) Corticolimbic dopamine
neurotransmission is temporally dissociated from the cognitive and
locomotor effects of phencyclidine. J. Neurosci. 18, 5545−5554.
(29) Jackson, M. E., Homayoun, H., and Moghaddam, B. (2004)
NMDA receptor hypofunction produces concomitant firing rate
potentiation and burst activity reduction in the prefrontal cortex. Proc.
Natl. Acad. Sci. U. S. A. 101, 8467−8472.
(30) Kelly, P. H., Seviour, P. W., and Iversen, S. D. (1975)
Amphetamine and apomorphine responses in the rat following 6-
OHDA lesions of the nucleus accumbens septi and corpus striatum.
Brain Res. 94, 507−522.
(31) Joyce, E. M., Stinus, L., and Iversen, S. D. (1983) Effect of
injections of 6-OHDA into either nucleus accumbens septi or frontal
cortex on spontaneous and drug-induced activity. Neuropharmacology
22, 1141−1145.
(32) Sharp, T., Zetterstrom, T., Ljungberg, T., and Ungerstedt, U.
(1987) A direct comparison of amphetamine-induced behaviours and
regional brain dopamine release in the rat using intracerebral dialysis.
Brain Res. 401, 322−330.
(33) Ljungberg, T., and Ungerstedt, U. (1985) A rapid and simple
behavioural screening method for simultaneous assessment of limbic
and striatal blocking effects of neuroleptic drugs. Pharmacol., Biochem.
Behav. 23, 479−485.
(34) Bubser, M., Keseberg, U., Notz, P. K., and Schmidt, W. J. (1992)
Differential behavioural and neurochemical effects of competitive and
non-competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol.
229, 75−82.
(35) Svensson, A., Pileblad, E., and Carlsson, M. (1991) A comparison
between the non-competitive NMDA antagonist dizocilpine (MK-801)
and the competitive NMDA antagonist D-CPPene with regard to
dopamine turnover and locomotor-stimulatory properties in mice . J.
Neural Transm.: Gen. Sect. 85, 117−129.
(36) Liljequist, S., Ossowska, K., Grabowska-Anden, M., and Anden, N.
E. (1991) Effect of the NMDA receptor antagonist, MK-801, on
locomotor activity and on the metabolism of dopamine in various brain
areas of mice. Eur. J. Pharmacol. 195, 55−61.
(37) Bartko, S. J., Romberg, C., White, B., Wess, J., Bussey, T. J., and
Saksida, L. M. (2011) Intact attentional processing but abnormal
(10) Shirey, J. K., Brady, A. E., Jones, P. J., Davis, A. A., Bridges, T. M.,
Kennedy, J. P., Jadhav, S. B., Menon, U. N., Xiang, Z., Watson, M. L.,
Christian, E. P., Doherty, J. J., Quirk, M. C., Snyder, D. H., Lah, J. J.,
Levey, A. I., Nicolle, M. M., Lindsley, C. W., and Conn, P. J. (2009) A
selective allosteric potentiator of the M1 muscarinic acetylcholine
receptor increases activity of medial prefrontal cortical neurons and
restores impairments in reversal learning. J. Neurosci. 29, 14271−14286.
(11) Marino, M. J., and Conn, P. J. (2002) Direct and indirect
modulation of the N-methyl D-aspartate receptor. Curr. Drug Targets:
CNS Neurol. Disord. 1, 1−16.
(12) Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T., and Conn, P.
J. (1998) Activation of the genetically defined M1 muscarinic receptor
potentiates N-methyl-D-asparate (NMDA) receptor currents in hippo-
campal pyramidal cells. Proc. Natl. Acad. Sci. U. S. A. 95, 11465−11470.
(13) Sur, C., Mallogora, P. J., Wittmann, M., al, e., Jacobson, M. A.,
Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick,
E. M., and Conn, P. J. (2003) N-Desmethylclozapine, an allosteric
agonist at muscarinic 1 receptor, potentiate N-methyl-D-aspartate
receptor activity. Proc. Natl. Acad. Sci. U. S. A. 100, 13674−13679.
(14) Digby, G. J., Noetzel, M. J., Bubser, M., Utley, T. J., Walker, A. G.,
Byun, N. E., Lebois, E. P., Xiang, Z., Sheffler, D. J., Cho, H. P., Davis, A.
A., Nemirovsky, N. E., Mennenga, S. E., Camp, B. W., Bimonte-Nelson,
H. A., Bode, J., Italiano, K., Morrison, R., Daniels, J. S., Niswender, C. M.,
Olive, M. F., Lindsley, C. W., Jones, C. K., and Conn, P. J. (2012) Novel
allosteric agonists of M1 muscarinic acetylcholine receptors induce brain
region-specific responses that correspond with behavioral effects in
animal models. J. Neurosci. 32, 8532−8544.
(15) Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S.
L., Rahnama, N. P., Nathanson, N. M., and Silva, A. J. (2003) Selective
cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant
mice. Nat. Neurosci. 6, 51−58.
(16) Brady, A. E., Jones, C. K., Bridges, T. M., Kennedy, J. P.,
Thompson, A. D., Heiman, J. U., Breininger, M. L., Gentry, P. R., Yin, H.,
Jadhav, S. B., Shirey, J. K., Conn, P. J., and Lindsley, C. W. (2008)
Centrally active allosteric potentiators of the M4 muscarinic acetylcho-
line receptor reverse amphetamine-induced hyperlocomotor activity in
rats. J. Pharmacol. Exp. Ther. 327, 941−953.
(17) Shirey, J. K., Xiang, Z., Orton, D., Brady, A. E., Johnson, K. A.,
Williams, R., Ayala, J. E., Rodriguez, A. L., Wess, J., Weaver, D.,
Niswender, C. M., and Conn, P. J. (2008) An allosteric potentiator of
M4 mAChR modulates hippocampal synaptic transmission. Nat. Chem.
Biol. 4, 42−50.
(18) Byun, N. E., Grannan, M., Bubser, M., Barry, R. L., Thompson, A.,
Rosanelli, J., Gowrishankar, R., Kelm, N. D., Damon, S., Bridges, T. M.,
Melancon, B. J., Tarr, J. C., Brogan, J. T., Avison, M. J., Deutch, A. Y.,
Wess, J., Wood, M. R., Lindsley, C. W., Gore, J. C., Conn, P. J., and Jones,
C. K. (2014) Antipsychotic drug-like effects of the selective M4
muscarinic acetylcholine receptor positive allosteric modulator
VU0152100. Neuropsychopharmacology 39, 1578−1593.
(19) Chan, W. Y., McKinzie, D. L., Bose, S., Mitchell, S. N., Witkin, J.
M., Thompson, R. C., Christopoulos, A., Lazareno, S., Birdsall, N. J.,
Bymaster, F. P., and Felder, C. C. (2008) Allosteric modulation of the
muscarinic M4 receptor as an approach to treating schizophrenia. Proc.
Natl. Acad. Sci. U. S. A. 105, 10978−10983.
(20) Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg,
A., Shaw, D. B., Sexton, P. M., and Christopoulos, A. (2010) Molecular
mechanisms of action and in vivo validation of an M4 muscarinic
acetylcholine receptor allosteric modulator with potential antipsychotic
properties. Neuropsychopharmacology 35, 855−869.
U
dx.doi.org/10.1021/cn500128b | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX